Účtovná hodnota akcie spoločnosti Kazia Therapeutics
Aká je hodnota metriky Účtovná hodnota akcie spoločnosti Kazia Therapeutics?
Hodnota metriky Účtovná hodnota akcie spoločnosti Kazia Therapeutics Limited je 0.07
Aká je definícia metriky Účtovná hodnota akcie?
Účtovná hodnota akcie (Book/Share) sa rovná majetku spoločnosti mínus záväzky spoločnosti podelené počtom vydaných akcií.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Účtovná hodnota akcie spoločností v sektore Health Care sektor na ASX v porovnaní so spoločnosťou Kazia Therapeutics
Čomu sa venuje spoločnosť Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Firmy s metrikou účtovná hodnota akcie podobnou spoločnosti Kazia Therapeutics
- Hodnota metriky Účtovná hodnota akcie spoločnosti Signal Gold je 0.07
- Hodnota metriky Účtovná hodnota akcie spoločnosti Absolute Software je 0.07
- Hodnota metriky Účtovná hodnota akcie spoločnosti Luxxu je 0.07
- Hodnota metriky Účtovná hodnota akcie spoločnosti Manfield Chemical je 0.07
- Hodnota metriky Účtovná hodnota akcie spoločnosti V1 je 0.07
- Hodnota metriky Účtovná hodnota akcie spoločnosti SRG Graphite je 0.07
- Hodnota metriky Účtovná hodnota akcie spoločnosti Kazia Therapeutics je 0.07
- Hodnota metriky Účtovná hodnota akcie spoločnosti Saferoads je 0.07
- Hodnota metriky Účtovná hodnota akcie spoločnosti K9 Gold je 0.07
- Hodnota metriky Účtovná hodnota akcie spoločnosti TWC Tech II je 0.07
- Hodnota metriky Účtovná hodnota akcie spoločnosti Mineworx Technologies je 0.07
- Hodnota metriky Účtovná hodnota akcie spoločnosti China Greenland Broad Greenstate je 0.07
- Hodnota metriky Účtovná hodnota akcie spoločnosti Patriot One Technologies je 0.07